Literature DB >> 24392325

Short term apoptotic activity of intravitreal bevacizumab on rabbit retina.

Fatih Mehmet Türkcü1, Mehmet Numan Alp2, Gül Türkcü3, Sezer Kulaçoğlu4, Gülcan Kural2.   

Abstract

AIM: To evaluate the safety and the short term apoptotic activity of intravitreal bevacizumab in rabbit eyes by histopathological analysis.
METHODS: Twenty-eight eyes of 14 rabbits were divided into three groups: 8 rabbits in group 1 and 3 rabbits in each of group 2 and group 3. Intravitreal bevacizumab (1.25mg/0.05mL) was applied to the right eyes of each subject in group 1 and group 2 (11 eyes) and the same volume of saline was applied to the left eyes of each subject in group 1 and group 3 (11 eyes). The left eyes in group 2 and the right eyes in group 3 were left untreated and used as control. Enucleated eyes were used for histopathologic analyses.
RESULTS: After immunohistochemical staining with caspase-3 and p53, there was no histological evidence of toxicity to the retina and the optic nerve in any of the sections that were analyzed in all three groups. In addition, vascular endothelial cells located at the retina and the optic nerve tissues in all groups showed a similar staining pattern with caspase-3 and p53.
CONCLUSION: Our study showed that intravitreal bevacizumab with the dose of 1.25mg/0.05mL caused no histological signs of toxicity or apoptotic activity on the rabbit retina.

Entities:  

Keywords:  apoptotic activity; bevacizumab; retina; toxicity

Year:  2013        PMID: 24392325      PMCID: PMC3874516          DOI: 10.3980/j.issn.2222-3959.2013.06.08

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  40 in total

1.  Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.

Authors:  Germaine Fuh; Ping Wu; Wei-Ching Liang; Mark Ultsch; Chingwei V Lee; Barbara Moffat; Christian Wiesmann
Journal:  J Biol Chem       Date:  2005-12-22       Impact factor: 5.157

2.  Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model.

Authors:  Sophie J Bakri; J Douglas Cameron; Colin A McCannel; Jose S Pulido; Ronald J Marler
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

3.  Intravitreal bevacizumab monotherapy for retinopathy of prematurity.

Authors:  Alparslan Şahin; Muhammed Şahin; Abdullah Kürşat Cingü; Yasin Çınar; Fatih Mehmet Türkcü; Harun Yüksel; Savaş Kaya; Şeyhmus Arı; İhsan Caça
Journal:  Pediatr Int       Date:  2013-07-30       Impact factor: 1.524

4.  Growth regulation of a cellular tumour antigen, p53, in nontransformed cells.

Authors:  N C Reich; A J Levine
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

Review 5.  Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.

Authors:  I Krämer; H-P Lipp
Journal:  J Clin Pharm Ther       Date:  2007-02       Impact factor: 2.512

6.  Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema.

Authors:  Mehmet Taş; Veysi Oner; Mehmet Fuat Alakuş; Fatih Mehmet Türkcü; Yalçın Işcan; Kemal Yüksel
Journal:  Int Ophthalmol       Date:  2013-01-19       Impact factor: 2.031

7.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

8.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Authors:  Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

9.  Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.

Authors:  Swaantje Peters; Peter Heiduschka; Sylvie Julien; Focke Ziemssen; Heike Fietz; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Am J Ophthalmol       Date:  2007-04-23       Impact factor: 5.258

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  1 in total

1.  Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab.

Authors:  Patricia Muñoz-Villegas; Alejandra Sanchez-Rios; Mayra G Quinonez-Alvarado; Oscar Olvera-Montaño; Juan D Quintana-Hau; Leopoldo Baiza-Duran
Journal:  J Exp Pharmacol       Date:  2021-05-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.